Icosavax Past Earnings Performance
Past criteria checks 0/6
Icosavax's earnings have been declining at an average annual rate of -46.5%, while the Biotechs industry saw earnings growing at 16.4% annually. Revenues have been declining at an average rate of 58.9% per year.
Key information
-46.5%
Earnings growth rate
37.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -58.9% |
| Return on equity | -41.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth
Jul 04
Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?
Mar 10Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?
Oct 18Icosavax GAAP EPS of -$0.57
Aug 15Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones
Jul 28Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Jun 22Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Mar 24We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely
Oct 29Revenue & Expenses BreakdownBeta
How Icosavax makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -97 | 36 | 0 |
| 30 Jun 23 | 0 | -97 | 35 | 0 |
| 31 Mar 23 | 0 | -93 | 33 | 0 |
| 31 Dec 22 | 1 | -92 | 30 | 0 |
| 30 Sep 22 | 3 | -86 | 7 | 0 |
| 30 Jun 22 | 4 | -99 | 24 | 0 |
| 31 Mar 22 | 6 | -85 | 19 | 0 |
| 31 Dec 21 | 8 | -67 | 14 | 0 |
| 30 Sep 21 | 7 | -53 | 29 | 0 |
| 30 Jun 21 | 6 | -25 | 5 | 0 |
| 31 Mar 21 | 4 | -21 | 3 | 0 |
| 31 Dec 20 | 2 | -19 | 3 | 0 |
Quality Earnings: ICVX is currently unprofitable.
Growing Profit Margin: ICVX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ICVX is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.
Accelerating Growth: Unable to compare ICVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ICVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.1%).
Return on Equity
High ROE: ICVX has a negative Return on Equity (-41.62%), as it is currently unprofitable.